Article
Response Predictors and Clonal Evolution during Thalidomide Therapy in Myelodysplastic Neoplasms with Increased Blasts
2026-08-25
Abstract excerpt
<title>Abstract</title> <p> Therapeutic options remain limited for patients with myelodysplastic neoplasms (MDS) with increased blasts who are ineligible for, intolerant of or decline hypomethylating agents (HMAs). We retrospectively investigated the efficacy, predictors of response, survival outcomes and clonal evolution of thalidomide in 56 patients with MDS and increased blasts. Among 50 evaluable patients, t...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 1ce7a946-f573-54b5-a928-3900f1d2d677
- DOI
- 10.21203/rs.3.rs-10536298/v1
